Trevi Therapeutics Newsroom

Trevi Therapeutics(TRVI.US) Officer Sells US$71,575.78 in Common Stock

$Trevi Therapeutics(TRVI.US)$ Officer GOOD JENNIFER L sold 25,037 shares of common stock on May 20, 2024 at an average price of $2.8588 for a total value of $71,575.78.Source: Announcement What is sta

Futu News05:14

Trevi Therapeutics(TRVI.US) Officer Sells US$13,276.2 in Common Stock

$Trevi Therapeutics(TRVI.US)$ Officer GOOD JENNIFER L sold 4,578 shares of common stock on May 10, 2024 at an average price of $2.9 for a total value of $13,276.2.Source: Announcement What is statemen

Futu NewsMay 15 05:34

Buy Rating Affirmed for Trevi Therapeutics Amid Promising Clinical Advances and Solid Financial Position

TipRanksMay 10 13:17

Analysts Are Bullish on These Healthcare Stocks: MariMed (MRMD), Trevi Therapeutics (TRVI)

TipRanksMay 10 02:00

Trevi Therapeutics to Participate in Upcoming Conferences

NEW HAVEN, Conn., May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) fo

Trevi TherapeuticsMay 9 12:00

Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham

Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham

Dow JonesMay 8 21:37

Analysts Are Bullish on These Healthcare Stocks: Trevi Therapeutics (TRVI), Neurogene (NGNE)

TipRanksMay 8 19:50

Trevi Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.

Trevi Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.

BenzingaMay 8 06:11

Trevi Therapeutics | 10-Q: Quarterly report

Futu NewsMay 8 04:17 · Announcements

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024

Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., May 1, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the i

Trevi TherapeuticsMay 1 12:00

Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic

BenzingaApr 9 19:32

Needham: Reiterates the Trevi Therapeutics (TRVI.US) rating, adjusted from buy to buy, with a target price of $8.00.

Needham: Reiterates the Trevi Therapeutics (TRVI.US) rating, adjusted from buy to buy, with a target price of $8.00.

Zhitong FinanceApr 9 18:10

Trevi Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 155.18% Needham → $8 Reiterates Buy → Buy 03/21/2024 187.08% Oppenheimer $9 → $9 Maintains Outp

BenzingaApr 9 18:04

CALM,PLAY and VNDA Are Among After Hour Movers

Seeking AlphaApr 3 04:43

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX)

TipRanksMar 25 09:30

Buy Rating for Trevi Therapeutics Anchored on Haduvio's Clinical Promise and Market Potential

TipRanksMar 22 20:05

Trevi Therapeutics Price Target Maintained With a $9.00/Share by Oppenheimer

Trevi Therapeutics Price Target Maintained With a $9.00/Share by Oppenheimer

Dow JonesMar 21 21:02

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (VOR), Roche Holding AG (OtherRHHVF) and Trevi Therapeutics (TRVI)

TipRanksMar 21 19:50

Trevi Therapeutics (TRVI) Receives a Buy From Stifel Nicolaus

TipRanksMar 21 19:27

Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target

Needham analyst Serge Belanger reiterates Trevi Therapeutics with a Buy and maintains $8 price target.

Analyst UpgradesMar 21 18:53